The Board - Guard Therapeutics

Johan Bygge

Chairman of the Board since 2026

Education: Master of Science from Stockholm School of Economics

Previous experience: Chairman of EQT Asia Pacific, COO EQT, CFO Investor AB, Deputy CEO Electrolux, CFO Electrolux. Board member of Anticimex, PSM Ltd, I-Med, ILA Vietnam, Sanitec Oy, Hi3G Scandinavia, Rådet för god sed på Aktiemarknaden, among others. Chairman of the Board of Guard Therapeutics International AB between 2021-2026.

Other assignments: Chairman of Arevo AB, Scandi Standard AB (publ), Regin AB and Q-linea AB. Deputy Chairman in Tredje AP-fonden. Board member of Getinge AB, Capman Oyj, Lantmännen Ek För and Riksbanken Jubileumsfond.

Holdings: 11,314 shares

Independent in relation to the Company and its management and the Company’s major shareholders.

Tobias Agervald

Non-Executive Member of the Board since 2026,

Education: MD and PhD from Uppsala University

Previous experience: Senior Medical Director at Astellas Pharma Global Clinical Development. Global key opinion leader in cardio-renal disease and frequently engaged expert for analysis of pharmaceutical development projects and design and execution of clinical studies via advisory boards and steering committees. He served as CEO of Guard Therapeutics International AB from 2019 until 2026.

Other assignments: Tobias Agervald is an adjunct associate professor at the Karolinska Institute and has been an expert consultant, lecturer or advisory board member for multiple pharmaceutical companies. Board member of Gulch Pharma (in the process of changing its name to Renity Pharma AB) and TE Medical Consulting AB.

Holdings: 33,009 shares

Independent in relation to the Company and its management and the Company’s major shareholders.

David Bejker

Non-Executive Member of the Board since 2023

Education: Master of Science from Stockholm School of Economics

Previous experience: David Bejker has extensive experience in the biotechnology industry, both as an investor and in business development. He previously worked at the venture capital firm HealthCap.

Other assignments: David Bejker is CEO of Affibody Medical AB, Board Member of Affibody AB and Amylonix AB.

Holdings: -

Independent in relation to the Company and its management and the Company’s major shareholders.

Gunilla Ekström

Non-Executive Member of the Board since 2021

Education: MD and Associate Professor (Docent) in Biochemical Toxicology, Karolinska Institute, Stockholm

Previous experience: Gunilla Ekström has previous experience from Astra Zeneca, Orexo, Karolinska Development and Ultimovacs.

Other assignments: Gunilla is co-founder of Gesynta Pharma AB, Board member of Corline Biomedical AB, Initiator Pharma AS, Strike Pharma AB and MyCural Therapeutics AB.

Holdings: 32,306 shares (after registration of the RTO)

Independent in relation to the Company and its management and the Company’s major shareholders.

Göran Forsberg

Non-Executive Member of the Board since 2026

Education: Master of Science in Engineering from Lund University, Faculty of Engineering. PhD in Biochemistry from KTH Royal Institute of Technology.

Previous experience: Göran has more than 30 years of experience in drug development across both the biotechnology industry and large pharmaceutical companies. He has extensive experience in multiple areas of drug development, as well as in business development and investor relations. He served as CEO of Cantargia AB from 2014 until February 2025. Prior to that, he was Director of Business Development at Active Biotech. His earlier experience includes positions at Pharmacia, KabiGen and the University of Adelaide in Australia, as well as serving as a board member of Isogenica Ltd. Member of the Board of Guard Therapeutics International AB between 2019-2026.

Other assignments: Chairman of Aventera Antibodies AB. Board Member of Mesenkia Therapeutics AB.

Holdings: 5,161 shares

Independent in relation to the Company and its management and the Company’s major shareholders.

Alexander Oker-Blom

Non-Executive Member of the Board

Education: Master of Science in Business and Economics from Stockholm University.

Previous experience: CEO of Alted AB. Previous board appointments include Nocom AB, IAR Systems AB, Orre & Nyberg Capital AB, among others.

Other assignments: Alexander Oker-Blom is Chair of the Board of AOB Förvaltning AB, Björn Oker-Bloms Minne, Disruptive Materials AB (publ), AB Måttex and Måttex Förvaltning AB. He is also a board member of Alted AB, Axema Access Control AB, Claëstorps Fideikommiss AB, Elon Group AB (publ), the Jacqueline Palmstierna Oker-Blom Foundation in memory of Jacob Palmstierna, and Nya Sällskapet.

Holdings: 1,170,595 shares (after registration of the RTO)

Independent in relation to the Company and its management. Not independent in relation to the Company’s major shareholders.